You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 28, 2025

Purepac Pharm Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for PUREPAC PHARM

PUREPAC PHARM has one hundred and thirty approved drugs.

There are two tentative approvals on PUREPAC PHARM drugs.

Summary for Purepac Pharm
US Patents:0
Tradenames:62
Ingredients:61
NDAs:130

Drugs and US Patents for Purepac Pharm

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Purepac Pharm DOXEPIN HYDROCHLORIDE doxepin hydrochloride CAPSULE;ORAL 073054-001 Dec 28, 1990 DISCN No No ⤷  Try for Free ⤷  Try for Free
Purepac Pharm PENICILLIN V POTASSIUM penicillin v potassium TABLET;ORAL 061571-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
Purepac Pharm PINDOLOL pindolol TABLET;ORAL 074125-002 Apr 28, 1993 DISCN No No ⤷  Try for Free ⤷  Try for Free
Purepac Pharm PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride TABLET;ORAL 070816-001 Nov 3, 1986 DISCN No No ⤷  Try for Free ⤷  Try for Free
Purepac Pharm TRIAMCINOLONE triamcinolone TABLET;ORAL 084020-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 5 of 5 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Purepac Pharm – Market Position, Strengths & Strategic Insights

Last updated: July 27, 2025

In the dynamic world of pharmaceuticals, understanding the competitive landscape is crucial for success. Purepac Pharmaceutical Company, a key player in the generic drug market, offers an intriguing case study for competitive analysis. This article delves into Purepac's market position, strengths, and strategic insights, providing valuable information for industry professionals and analysts.

The Rise of Purepac Pharmaceutical

Purepac Pharmaceutical Company has established itself as a significant player in the generic drug market. The company's focus on producing high-quality, affordable medications has positioned it as a formidable competitor in the pharmaceutical industry.

Purepac's Market Entry and Growth

Purepac's journey in the pharmaceutical industry began with a focus on generic drugs. The company strategically entered the market by targeting high-demand medications with expiring patents. This approach allowed Purepac to quickly establish a presence in the competitive generic drug landscape[1].

Purepac's Market Position

Purepac has carved out a notable position in the generic drug market, particularly in the area of anti-inflammatory medications. The company's success in securing FDA approvals for its generic products has been a key factor in its market growth.

FDA Approvals and Market Impact

Purepac's ability to secure FDA approvals for its generic drugs has been crucial to its market position. In 1993, Purepac was one of five generic drug makers to win FDA approval to sell naproxen, a generic version of the blockbuster arthritis drug Naprosyn[1]. This approval positioned Purepac to compete directly with established pharmaceutical giants like Syntex Corp.

Purepac said it is one of five makers of generic drugs that have won FDA approval to sell naproxen. Syntex's Hamilton Pharma Inc. has been selling a generic version of Naprosyn since August[1].

Competitive Edge in Anti-Inflammatory Drugs

Purepac's success in the anti-inflammatory drug market, particularly with naproxen, demonstrates its ability to compete effectively in high-value generic drug categories. This success has likely contributed to the company's overall market position and reputation in the pharmaceutical industry.

Purepac's Strengths and Capabilities

Purepac's strengths lie in its ability to develop and manufacture high-quality generic drugs efficiently. The company's focus on key therapeutic areas and its expertise in navigating the regulatory landscape have been crucial to its success.

Manufacturing Expertise

Purepac's manufacturing capabilities allow it to produce generic drugs at scale, ensuring a steady supply to meet market demand. This expertise is particularly valuable in the competitive generic drug market, where efficiency and quality are paramount.

Regulatory Navigation

The company's success in securing FDA approvals demonstrates its proficiency in navigating the complex regulatory landscape of the pharmaceutical industry. This capability is a significant strength, allowing Purepac to bring its generic products to market efficiently.

Strategic Insights: Purepac's Approach to Market Competition

Purepac's strategic approach to market competition offers valuable insights for pharmaceutical companies looking to establish or strengthen their position in the generic drug market.

Focus on High-Demand Generics

Purepac's strategy of targeting high-demand medications with expiring patents has proven effective. This approach allows the company to enter markets with established demand, reducing the risk associated with new product launches.

Rapid Market Entry

The company's ability to secure FDA approvals quickly and efficiently enables rapid market entry. This strategy allows Purepac to capitalize on opportunities as soon as patents expire, gaining a competitive edge in the race to market generic alternatives.

Challenges and Opportunities in the Generic Drug Market

The generic drug market presents both challenges and opportunities for companies like Purepac. Understanding these factors is crucial for developing effective strategies and maintaining a competitive edge.

Patent Expirations and Market Opportunities

Patent expirations on branded drugs create significant opportunities for generic drug manufacturers. As noted by industry analyst David Saks, "When your quarterback ages and you don't get a replacement, it becomes very important" to develop new drugs[1]. This analogy aptly describes the opportunity for generic drug makers to step in when patents expire on popular medications.

Intense Competition and Price Pressures

The generic drug market is characterized by intense competition and significant price pressures. As analyst Hemant Shah predicted in 1993, "This is going to be one of the most ruthless markets"[1]. This competitive landscape requires companies like Purepac to continually innovate and optimize their operations to remain profitable.

The Impact of Regulatory Changes on Purepac's Strategy

Regulatory changes can significantly impact the strategies of pharmaceutical companies. For Purepac, staying ahead of regulatory trends and adapting quickly to changes is crucial for maintaining its competitive position.

Abbreviated New Drug Applications (ANDAs)

The FDA's Abbreviated New Drug Application (ANDA) process has been a key factor in Purepac's ability to bring generic drugs to market quickly. This streamlined approval process for generic drugs has allowed companies like Purepac to compete more effectively with branded drug manufacturers.

Quality Control and Manufacturing Standards

Maintaining high quality control and adhering to stringent manufacturing standards is essential for Purepac's continued success. As regulatory bodies increase their focus on quality and safety, Purepac's ability to meet and exceed these standards will be crucial for maintaining its market position.

Purepac's Role in Increasing Drug Accessibility

One of the key benefits of generic drug manufacturers like Purepac is their role in increasing drug accessibility. By producing affordable alternatives to branded medications, Purepac helps make essential treatments more accessible to a broader population.

Cost Savings for Consumers and Healthcare Systems

Generic drugs typically cost significantly less than their branded counterparts. Purepac's products contribute to substantial cost savings for both individual consumers and healthcare systems as a whole. This cost reduction can lead to improved medication adherence and better health outcomes.

Expanding Market Reach

By offering more affordable options, Purepac and other generic drug manufacturers help expand the reach of important medications. This expansion can lead to improved public health outcomes and increased market size for pharmaceutical products overall.

Purepac's Research and Development Efforts

While Purepac primarily focuses on generic drugs, research and development (R&D) remain crucial for the company's long-term success. R&D efforts in generic drug manufacturing often focus on improving formulations, developing more efficient production processes, and exploring new drug delivery systems.

Formulation Improvements

Purepac's R&D efforts likely include work on improving drug formulations to enhance efficacy, reduce side effects, or improve patient compliance. These improvements can provide a competitive edge in the generic drug market.

Production Process Optimization

Investing in R&D to optimize production processes can lead to significant cost savings and improved product quality. This focus on efficiency is crucial in the highly competitive generic drug market.

Purepac's Market Expansion Strategies

To maintain and grow its market position, Purepac likely employs various market expansion strategies. These strategies may include entering new geographic markets, expanding its product portfolio, and forming strategic partnerships.

Geographic Expansion

Expanding into new geographic markets can provide significant growth opportunities for Purepac. This may involve navigating different regulatory environments and adapting to local market conditions.

Product Portfolio Diversification

Diversifying its product portfolio allows Purepac to reduce risk and capitalize on new market opportunities. This may involve expanding into new therapeutic areas or developing more complex generic formulations.

The Role of Partnerships and Collaborations

In the pharmaceutical industry, partnerships and collaborations can play a crucial role in a company's success. For Purepac, strategic partnerships could provide access to new technologies, markets, or resources.

Manufacturing Partnerships

Collaborations with contract manufacturing organizations (CMOs) can help Purepac expand its production capacity or access specialized manufacturing capabilities.

Research Collaborations

Partnerships with academic institutions or other pharmaceutical companies can enhance Purepac's R&D capabilities, potentially leading to innovative generic formulations or new drug delivery systems.

Future Outlook for Purepac and the Generic Drug Market

The future of the generic drug market, and Purepac's position within it, will be shaped by various factors including technological advancements, regulatory changes, and evolving healthcare needs.

Emerging Technologies in Drug Manufacturing

Advancements in manufacturing technologies, such as continuous manufacturing and 3D printing, could significantly impact the generic drug industry. Companies that can effectively leverage these technologies may gain a competitive advantage.

Biosimilars and Complex Generics

The growing market for biosimilars and complex generic drugs presents both opportunities and challenges for companies like Purepac. Success in these areas requires significant investment in R&D and manufacturing capabilities.

Key Takeaways

  • Purepac Pharmaceutical Company has established a strong position in the generic drug market, particularly in anti-inflammatory medications.
  • The company's success is largely due to its ability to secure FDA approvals quickly and efficiently.
  • Purepac's focus on high-demand generics and rapid market entry has been a key strategic advantage.
  • The generic drug market is highly competitive, with significant price pressures and regulatory challenges.
  • Purepac plays a crucial role in increasing drug accessibility by offering affordable alternatives to branded medications.
  • Future success for Purepac will likely depend on its ability to navigate regulatory changes, invest in R&D, and potentially expand into new markets or product categories.

FAQs

  1. What is Purepac Pharmaceutical Company's main focus? Purepac primarily focuses on developing and manufacturing generic drugs, with a particular strength in anti-inflammatory medications.

  2. How does Purepac compete in the pharmaceutical market? Purepac competes by quickly securing FDA approvals for generic drugs, focusing on high-demand medications with expiring patents, and efficiently manufacturing quality products.

  3. What are the main challenges facing generic drug manufacturers like Purepac? Key challenges include intense competition, price pressures, regulatory hurdles, and the need to continually innovate and optimize operations.

  4. How do generic drug manufacturers like Purepac impact drug accessibility? By producing affordable alternatives to branded medications, companies like Purepac help make essential treatments more accessible to a broader population, potentially improving public health outcomes.

  5. What future trends might affect Purepac's market position? Emerging technologies in drug manufacturing, the growing market for biosimilars and complex generics, and potential regulatory changes could all significantly impact Purepac's future market position.

Sources cited: [1] https://www.latimes.com/archives/la-xpm-1993-09-30-fi-40495-story.html

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.